John Arcaroli
Concepts (368)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 19 | 2018 | 791 | 2.540 |
Why?
| | Xenograft Model Antitumor Assays | 21 | 2024 | 868 | 1.480 |
Why?
| | Antineoplastic Agents | 17 | 2018 | 2122 | 1.360 |
Why?
| | Drug Resistance, Neoplasm | 7 | 2016 | 800 | 1.040 |
Why?
| | Benzodioxoles | 3 | 2012 | 115 | 1.010 |
Why?
| | Quinazolines | 4 | 2012 | 250 | 1.010 |
Why?
| | Camptothecin | 4 | 2016 | 115 | 0.900 |
Why?
| | Receptor, Notch1 | 3 | 2015 | 64 | 0.860 |
Why?
| | Aldehyde Dehydrogenase | 6 | 2017 | 100 | 0.860 |
Why?
| | Mice, Nude | 16 | 2024 | 696 | 0.800 |
Why?
| | Haplotypes | 4 | 2012 | 494 | 0.750 |
Why?
| | Phosphatidylinositol 3-Kinases | 10 | 2018 | 366 | 0.710 |
Why?
| | Gene Dosage | 3 | 2015 | 140 | 0.640 |
Why?
| | Wnt Signaling Pathway | 5 | 2024 | 192 | 0.630 |
Why?
| | Neutrophils | 13 | 2007 | 1236 | 0.620 |
Why?
| | src-Family Kinases | 3 | 2017 | 92 | 0.600 |
Why?
| | Pancreatic Neoplasms | 6 | 2024 | 935 | 0.590 |
Why?
| | Amyloid Precursor Protein Secretases | 3 | 2014 | 80 | 0.590 |
Why?
| | Endotoxemia | 9 | 2004 | 86 | 0.580 |
Why?
| | Anilides | 2 | 2018 | 73 | 0.580 |
Why?
| | Enzyme Inhibitors | 5 | 2016 | 839 | 0.570 |
Why?
| | Protein Kinase Inhibitors | 9 | 2018 | 916 | 0.570 |
Why?
| | Biomarkers, Tumor | 9 | 2018 | 1272 | 0.540 |
Why?
| | Mice | 41 | 2024 | 17733 | 0.530 |
Why?
| | Acute Lung Injury | 2 | 2011 | 287 | 0.520 |
Why?
| | Pyridines | 4 | 2018 | 506 | 0.510 |
Why?
| | Receptors, Notch | 2 | 2015 | 88 | 0.500 |
Why?
| | Tankyrases | 1 | 2016 | 15 | 0.500 |
Why?
| | Cell Line, Tumor | 21 | 2024 | 3405 | 0.490 |
Why?
| | Drug Discovery | 1 | 2016 | 141 | 0.480 |
Why?
| | Polymorphism, Genetic | 3 | 2007 | 659 | 0.460 |
Why?
| | NF-kappa B | 13 | 2007 | 691 | 0.460 |
Why?
| | 3' Untranslated Regions | 2 | 2012 | 145 | 0.450 |
Why?
| | DNA Copy Number Variations | 1 | 2015 | 182 | 0.440 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 86 | 0.440 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2014 | 75 | 0.430 |
Why?
| | Tetrahydronaphthalenes | 1 | 2013 | 29 | 0.410 |
Why?
| | Valine | 1 | 2013 | 82 | 0.410 |
Why?
| | Animals | 44 | 2024 | 36823 | 0.390 |
Why?
| | Mitogen-Activated Protein Kinases | 7 | 2014 | 313 | 0.380 |
Why?
| | Sepsis | 3 | 2007 | 614 | 0.360 |
Why?
| | Lipopolysaccharides | 9 | 2007 | 886 | 0.350 |
Why?
| | Signal Transduction | 17 | 2018 | 5075 | 0.350 |
Why?
| | Proto-Oncogene Proteins | 8 | 2018 | 647 | 0.340 |
Why?
| | Superoxide Dismutase | 3 | 2008 | 346 | 0.330 |
Why?
| | Urokinase-Type Plasminogen Activator | 2 | 2007 | 29 | 0.330 |
Why?
| | Cell Proliferation | 13 | 2024 | 2472 | 0.320 |
Why?
| | Interleukins | 1 | 2011 | 250 | 0.310 |
Why?
| | Neoplasm Metastasis | 4 | 2016 | 657 | 0.310 |
Why?
| | Hemorrhage | 6 | 2004 | 721 | 0.310 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 3 | 2014 | 95 | 0.300 |
Why?
| | Heterografts | 3 | 2018 | 138 | 0.290 |
Why?
| | HCT116 Cells | 4 | 2018 | 80 | 0.280 |
Why?
| | Apoptosis | 11 | 2018 | 2551 | 0.270 |
Why?
| | SOXB1 Transcription Factors | 2 | 2018 | 61 | 0.270 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2024 | 287 | 0.270 |
Why?
| | Azepines | 2 | 2018 | 90 | 0.260 |
Why?
| | Benzimidazoles | 3 | 2013 | 170 | 0.260 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1249 | 0.260 |
Why?
| | Mutation | 3 | 2012 | 3946 | 0.250 |
Why?
| | Immunoblotting | 5 | 2015 | 306 | 0.250 |
Why?
| | Neutrophil Activation | 5 | 2003 | 80 | 0.230 |
Why?
| | Receptors, Interleukin-1 | 1 | 2006 | 216 | 0.230 |
Why?
| | beta Catenin | 3 | 2016 | 253 | 0.230 |
Why?
| | Humans | 46 | 2024 | 136764 | 0.230 |
Why?
| | TOR Serine-Threonine Kinases | 4 | 2018 | 412 | 0.220 |
Why?
| | Oligonucleotide Array Sequence Analysis | 6 | 2015 | 766 | 0.220 |
Why?
| | Pyrimidines | 2 | 2018 | 470 | 0.210 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2006 | 455 | 0.210 |
Why?
| | Adrenergic alpha-Antagonists | 2 | 2002 | 34 | 0.210 |
Why?
| | Mice, Inbred BALB C | 10 | 2003 | 1269 | 0.210 |
Why?
| | Proto-Oncogene Proteins c-akt | 8 | 2018 | 437 | 0.210 |
Why?
| | Colonic Neoplasms | 2 | 2016 | 254 | 0.200 |
Why?
| | Adrenergic alpha-Agonists | 1 | 2002 | 28 | 0.200 |
Why?
| | Proto-Oncogene Proteins c-raf | 1 | 2002 | 45 | 0.200 |
Why?
| | Female | 24 | 2018 | 72787 | 0.190 |
Why?
| | Genetic Predisposition to Disease | 1 | 2011 | 2412 | 0.190 |
Why?
| | Neuroimmunomodulation | 1 | 2002 | 65 | 0.190 |
Why?
| | Aged | 11 | 2016 | 23794 | 0.190 |
Why?
| | ras Proteins | 3 | 2013 | 153 | 0.190 |
Why?
| | Adrenergic beta-Agonists | 1 | 2002 | 133 | 0.180 |
Why?
| | Middle Aged | 12 | 2016 | 33228 | 0.180 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2002 | 323 | 0.180 |
Why?
| | Hemoptysis | 1 | 2000 | 36 | 0.170 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2011 | 2184 | 0.170 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2012 | 317 | 0.160 |
Why?
| | Adult | 11 | 2016 | 37630 | 0.160 |
Why?
| | Cytokines | 4 | 2005 | 2083 | 0.160 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2016 | 683 | 0.160 |
Why?
| | Head and Neck Neoplasms | 2 | 2016 | 604 | 0.150 |
Why?
| | Male | 24 | 2016 | 67309 | 0.150 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2018 | 327 | 0.150 |
Why?
| | DNA Topoisomerases, Type II | 2 | 2016 | 45 | 0.150 |
Why?
| | Transplantation, Heterologous | 2 | 2016 | 194 | 0.150 |
Why?
| | CDC2 Protein Kinase | 1 | 2018 | 31 | 0.150 |
Why?
| | MAP Kinase Kinase Kinases | 2 | 2015 | 73 | 0.140 |
Why?
| | Oncogene Proteins v-abl | 1 | 2017 | 5 | 0.140 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 4 | 2003 | 145 | 0.140 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 3 | 2010 | 134 | 0.140 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 6 | 2007 | 283 | 0.140 |
Why?
| | Dasatinib | 1 | 2017 | 54 | 0.140 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 5 | 2016 | 267 | 0.140 |
Why?
| | Immunohistochemistry | 5 | 2017 | 1733 | 0.140 |
Why?
| | Case-Control Studies | 3 | 2011 | 3540 | 0.140 |
Why?
| | Gene Expression Profiling | 4 | 2018 | 1772 | 0.130 |
Why?
| | Angiogenesis Inhibitors | 2 | 2018 | 226 | 0.130 |
Why?
| | Neovascularization, Pathologic | 2 | 2018 | 301 | 0.130 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2015 | 382 | 0.130 |
Why?
| | Receptors, Cell Surface | 2 | 2012 | 382 | 0.130 |
Why?
| | Phosphatidylinositol 3-Kinase | 1 | 2016 | 26 | 0.130 |
Why?
| | Adenocarcinoma | 2 | 2014 | 938 | 0.130 |
Why?
| | Axin Protein | 1 | 2016 | 19 | 0.130 |
Why?
| | Aurora Kinase A | 1 | 2016 | 56 | 0.130 |
Why?
| | Corynebacterium | 1 | 2017 | 49 | 0.130 |
Why?
| | Corynebacterium Infections | 1 | 2017 | 41 | 0.130 |
Why?
| | Antigens, Neoplasm | 2 | 2016 | 319 | 0.130 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2016 | 23 | 0.130 |
Why?
| | Neoplasms, Experimental | 1 | 2017 | 176 | 0.120 |
Why?
| | Cell Cycle | 5 | 2018 | 601 | 0.120 |
Why?
| | Neoplastic Stem Cells | 2 | 2018 | 399 | 0.120 |
Why?
| | Autophagy | 1 | 2018 | 280 | 0.120 |
Why?
| | Serrate-Jagged Proteins | 1 | 2015 | 27 | 0.120 |
Why?
| | Jagged-1 Protein | 1 | 2015 | 23 | 0.120 |
Why?
| | Neoplasms | 3 | 2016 | 2644 | 0.120 |
Why?
| | Genotype | 3 | 2012 | 1914 | 0.120 |
Why?
| | Aged, 80 and over | 5 | 2014 | 7585 | 0.120 |
Why?
| | RNA, Small Interfering | 2 | 2015 | 622 | 0.120 |
Why?
| | RNA, Messenger | 5 | 2016 | 2831 | 0.120 |
Why?
| | Drug Synergism | 2 | 2014 | 382 | 0.120 |
Why?
| | Gene Duplication | 1 | 2015 | 68 | 0.120 |
Why?
| | Retinaldehyde | 1 | 2015 | 4 | 0.120 |
Why?
| | HMGB1 Protein | 2 | 2007 | 50 | 0.120 |
Why?
| | Pyrazoles | 1 | 2018 | 423 | 0.120 |
Why?
| | Acetaldehyde | 1 | 2015 | 17 | 0.120 |
Why?
| | Chemokines | 5 | 2003 | 228 | 0.110 |
Why?
| | Pyrimidinones | 1 | 2015 | 113 | 0.110 |
Why?
| | Acridines | 1 | 2014 | 7 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 1682 | 0.110 |
Why?
| | Neoplasm Transplantation | 4 | 2016 | 257 | 0.110 |
Why?
| | Chemokine CXCL2 | 4 | 2001 | 43 | 0.110 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2014 | 25 | 0.110 |
Why?
| | Respiration, Artificial | 2 | 2011 | 642 | 0.110 |
Why?
| | Benzazepines | 1 | 2014 | 39 | 0.110 |
Why?
| | Wnt Proteins | 1 | 2015 | 133 | 0.110 |
Why?
| | Pyridones | 1 | 2015 | 168 | 0.110 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 218 | 0.110 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 613 | 0.110 |
Why?
| | Gene Expression Regulation | 2 | 2007 | 2605 | 0.110 |
Why?
| | Cell Growth Processes | 1 | 2013 | 52 | 0.100 |
Why?
| | Cellular Senescence | 1 | 2015 | 186 | 0.100 |
Why?
| | Insulin-Like Growth Factor Binding Protein 2 | 1 | 2012 | 8 | 0.100 |
Why?
| | Random Allocation | 1 | 2013 | 353 | 0.100 |
Why?
| | Tumor Suppressor Proteins | 1 | 2015 | 327 | 0.100 |
Why?
| | Disease Models, Animal | 4 | 2018 | 4281 | 0.100 |
Why?
| | Enzyme Activation | 6 | 2003 | 810 | 0.100 |
Why?
| | DNA-Binding Proteins | 3 | 2016 | 1501 | 0.100 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 3 | 2017 | 23 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 411 | 0.100 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 327 | 0.100 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 81 | 0.100 |
Why?
| | Receptors, CXCR4 | 1 | 2012 | 86 | 0.090 |
Why?
| | Cyclosporine | 1 | 2013 | 268 | 0.090 |
Why?
| | Linkage Disequilibrium | 2 | 2012 | 268 | 0.090 |
Why?
| | Immunoprecipitation | 1 | 2012 | 155 | 0.090 |
Why?
| | Lung Diseases | 3 | 2004 | 767 | 0.090 |
Why?
| | Hydroxamic Acids | 1 | 2011 | 89 | 0.090 |
Why?
| | Lung | 8 | 2004 | 4052 | 0.090 |
Why?
| | Melanoma | 1 | 2018 | 757 | 0.090 |
Why?
| | Prognosis | 3 | 2015 | 4013 | 0.090 |
Why?
| | Peroxidase | 2 | 2002 | 175 | 0.090 |
Why?
| | Genetic Markers | 1 | 2012 | 344 | 0.090 |
Why?
| | Drug Design | 1 | 2012 | 167 | 0.090 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 162 | 0.090 |
Why?
| | Sirolimus | 1 | 2012 | 275 | 0.090 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2013 | 801 | 0.080 |
Why?
| | Genetic Association Studies | 1 | 2012 | 375 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2011 | 210 | 0.080 |
Why?
| | Administration, Oral | 1 | 2012 | 813 | 0.080 |
Why?
| | Phosphorylation | 3 | 2018 | 1758 | 0.080 |
Why?
| | Cetuximab | 3 | 2016 | 95 | 0.080 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2004 | 1242 | 0.080 |
Why?
| | Cell Separation | 1 | 2010 | 317 | 0.080 |
Why?
| | Membrane Proteins | 1 | 2015 | 1163 | 0.070 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 2 | 2018 | 44 | 0.070 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2016 | 1396 | 0.070 |
Why?
| | Antibodies, Monoclonal | 1 | 2015 | 1430 | 0.070 |
Why?
| | Models, Statistical | 1 | 2012 | 667 | 0.070 |
Why?
| | Genetic Variation | 2 | 2012 | 985 | 0.070 |
Why?
| | HT29 Cells | 2 | 2018 | 40 | 0.070 |
Why?
| | Cells, Cultured | 6 | 2007 | 4190 | 0.070 |
Why?
| | Gene Expression | 2 | 2003 | 1500 | 0.070 |
Why?
| | Europe | 1 | 2007 | 413 | 0.060 |
Why?
| | ErbB Receptors | 3 | 2016 | 613 | 0.060 |
Why?
| | Flow Cytometry | 1 | 2010 | 1177 | 0.060 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 1044 | 0.060 |
Why?
| | Thymine | 1 | 2006 | 15 | 0.060 |
Why?
| | Genome, Human | 1 | 2008 | 423 | 0.060 |
Why?
| | Cytosine | 1 | 2006 | 49 | 0.060 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2006 | 30 | 0.060 |
Why?
| | Phentolamine | 2 | 2002 | 15 | 0.060 |
Why?
| | Tumor Burden | 2 | 2018 | 309 | 0.060 |
Why?
| | Inflammation Mediators | 2 | 2006 | 513 | 0.060 |
Why?
| | Homozygote | 1 | 2006 | 203 | 0.060 |
Why?
| | MAP Kinase Kinase 2 | 2 | 2002 | 28 | 0.060 |
Why?
| | Translocation, Genetic | 1 | 2006 | 105 | 0.060 |
Why?
| | Propranolol | 2 | 2002 | 50 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 974 | 0.060 |
Why?
| | MicroRNAs | 1 | 2012 | 692 | 0.060 |
Why?
| | Survival Analysis | 1 | 2008 | 1321 | 0.060 |
Why?
| | MAP Kinase Kinase 1 | 2 | 2002 | 75 | 0.060 |
Why?
| | Adolescent | 3 | 2011 | 21382 | 0.060 |
Why?
| | Cell Nucleus | 2 | 2006 | 617 | 0.060 |
Why?
| | Spheroids, Cellular | 2 | 2016 | 76 | 0.060 |
Why?
| | Models, Biological | 2 | 2018 | 1773 | 0.060 |
Why?
| | Introns | 1 | 2006 | 256 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2002 | 152 | 0.060 |
Why?
| | Heat-Shock Proteins | 1 | 2005 | 142 | 0.060 |
Why?
| | Exons | 1 | 2006 | 351 | 0.060 |
Why?
| | Bone Marrow Cells | 2 | 2003 | 316 | 0.060 |
Why?
| | Neoplasm Invasiveness | 2 | 2016 | 507 | 0.050 |
Why?
| | Positron-Emission Tomography | 2 | 2018 | 293 | 0.050 |
Why?
| | Cause of Death | 1 | 2006 | 430 | 0.050 |
Why?
| | Shock, Septic | 1 | 2006 | 219 | 0.050 |
Why?
| | Oxidants | 1 | 2003 | 111 | 0.050 |
Why?
| | Organoids | 1 | 2024 | 112 | 0.050 |
Why?
| | Deoxycytidine | 1 | 2024 | 179 | 0.050 |
Why?
| | Paclitaxel | 1 | 2024 | 227 | 0.050 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2002 | 21 | 0.050 |
Why?
| | Brimonidine Tartrate | 1 | 2002 | 10 | 0.050 |
Why?
| | Models, Genetic | 1 | 2005 | 599 | 0.050 |
Why?
| | Phenylephrine | 1 | 2002 | 75 | 0.050 |
Why?
| | RNA Interference | 2 | 2016 | 466 | 0.050 |
Why?
| | Quinoxalines | 1 | 2002 | 66 | 0.050 |
Why?
| | Isoenzymes | 1 | 2003 | 304 | 0.050 |
Why?
| | Hydrogen Peroxide | 1 | 2003 | 327 | 0.050 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2002 | 434 | 0.050 |
Why?
| | Transcription, Genetic | 2 | 2006 | 1455 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2489 | 0.050 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 135 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 500 | 0.040 |
Why?
| | Free Radical Scavengers | 1 | 2001 | 88 | 0.040 |
Why?
| | Neoplasm Proteins | 3 | 2016 | 434 | 0.040 |
Why?
| | High Mobility Group Proteins | 1 | 2000 | 44 | 0.040 |
Why?
| | Imidazoles | 1 | 2001 | 238 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2002 | 320 | 0.040 |
Why?
| | Neutropenia | 1 | 2000 | 146 | 0.040 |
Why?
| | Interleukin-1 | 2 | 2000 | 964 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2002 | 465 | 0.040 |
Why?
| | Transcriptome | 2 | 2016 | 969 | 0.040 |
Why?
| | Nuclear Proteins | 2 | 2001 | 712 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2000 | 226 | 0.040 |
Why?
| | Trans-Activators | 1 | 2001 | 398 | 0.040 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2018 | 24 | 0.040 |
Why?
| | Colorado | 1 | 2008 | 4518 | 0.040 |
Why?
| | 4-Aminobenzoic Acid | 1 | 2018 | 7 | 0.040 |
Why?
| | Up-Regulation | 2 | 2016 | 843 | 0.030 |
Why?
| | Biomarkers | 1 | 2008 | 4143 | 0.030 |
Why?
| | Protein Transport | 1 | 2018 | 443 | 0.030 |
Why?
| | Pneumonia | 1 | 2003 | 635 | 0.030 |
Why?
| | Retinal Dehydrogenase | 1 | 2016 | 29 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 1 | 2016 | 90 | 0.030 |
Why?
| | Hyaluronan Receptors | 1 | 2016 | 102 | 0.030 |
Why?
| | Blotting, Western | 2 | 2013 | 1225 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2016 | 57 | 0.030 |
Why?
| | Protein Interaction Maps | 1 | 2016 | 48 | 0.030 |
Why?
| | Mice, Inbred C57BL | 4 | 2015 | 5735 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 121 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2016 | 194 | 0.030 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2016 | 138 | 0.030 |
Why?
| | Papillomaviridae | 1 | 2016 | 126 | 0.030 |
Why?
| | Prospective Studies | 1 | 2007 | 7572 | 0.030 |
Why?
| | S-Phase Kinase-Associated Proteins | 1 | 2015 | 20 | 0.030 |
Why?
| | Diphenylamine | 1 | 2014 | 9 | 0.030 |
Why?
| | Iloprost | 1 | 2015 | 45 | 0.030 |
Why?
| | Acid Phosphatase | 1 | 2014 | 20 | 0.030 |
Why?
| | Cadherins | 1 | 2016 | 205 | 0.030 |
Why?
| | Rhodamines | 1 | 2014 | 20 | 0.030 |
Why?
| | G2 Phase | 1 | 2014 | 38 | 0.030 |
Why?
| | Cell Division | 1 | 2016 | 792 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2016 | 283 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2016 | 953 | 0.030 |
Why?
| | Young Adult | 1 | 2011 | 13129 | 0.030 |
Why?
| | Inflammation | 1 | 2005 | 2834 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2016 | 209 | 0.030 |
Why?
| | Tretinoin | 1 | 2015 | 123 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2016 | 452 | 0.030 |
Why?
| | Benzamides | 1 | 2014 | 216 | 0.030 |
Why?
| | Antigens, CD | 1 | 2016 | 521 | 0.030 |
Why?
| | Transfection | 1 | 2016 | 941 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2011 | 15504 | 0.030 |
Why?
| | Receptor, Notch2 | 1 | 2013 | 15 | 0.030 |
Why?
| | Gonanes | 1 | 2013 | 27 | 0.030 |
Why?
| | Alphapapillomavirus | 1 | 2013 | 39 | 0.030 |
Why?
| | Receptors, CXCR | 1 | 2012 | 3 | 0.020 |
Why?
| | Erlotinib Hydrochloride | 1 | 2012 | 72 | 0.020 |
Why?
| | Cyclin D1 | 1 | 2012 | 68 | 0.020 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2003 | 41 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2014 | 685 | 0.020 |
Why?
| | Protein Binding | 1 | 2018 | 2216 | 0.020 |
Why?
| | Active Transport, Cell Nucleus | 2 | 2003 | 123 | 0.020 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2016 | 528 | 0.020 |
Why?
| | Computers | 1 | 2012 | 70 | 0.020 |
Why?
| | Mice, Inbred C3H | 2 | 2004 | 269 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2012 | 199 | 0.020 |
Why?
| | Niacinamide | 1 | 2012 | 79 | 0.020 |
Why?
| | Phenylurea Compounds | 1 | 2012 | 96 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2012 | 330 | 0.020 |
Why?
| | Injections, Intraperitoneal | 2 | 2001 | 114 | 0.020 |
Why?
| | Mice, Knockout | 3 | 2003 | 3003 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2012 | 139 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2003 | 233 | 0.020 |
Why?
| | Calcium Signaling | 1 | 2013 | 249 | 0.020 |
Why?
| | Xanthine Oxidase | 2 | 2001 | 81 | 0.020 |
Why?
| | Acute Disease | 2 | 2004 | 1004 | 0.020 |
Why?
| | United States | 1 | 2007 | 14691 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2011 | 497 | 0.020 |
Why?
| | Ligands | 1 | 2011 | 661 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 543 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2011 | 340 | 0.020 |
Why?
| | Survival Rate | 1 | 2014 | 1962 | 0.020 |
Why?
| | Models, Molecular | 1 | 2014 | 1570 | 0.020 |
Why?
| | Computational Biology | 1 | 2013 | 643 | 0.020 |
Why?
| | Tumor Microenvironment | 1 | 2012 | 672 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2012 | 2052 | 0.020 |
Why?
| | Cell Movement | 1 | 2011 | 965 | 0.020 |
Why?
| | Adiposity | 1 | 2012 | 518 | 0.020 |
Why?
| | Mice, Transgenic | 2 | 2003 | 2160 | 0.020 |
Why?
| | Calcium | 1 | 2013 | 1197 | 0.020 |
Why?
| | Oxidative Stress | 2 | 2003 | 1314 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3555 | 0.020 |
Why?
| | Neutrophil Infiltration | 1 | 2004 | 107 | 0.010 |
Why?
| | Permeability | 1 | 2004 | 161 | 0.010 |
Why?
| | Transcription Factor AP-1 | 1 | 2003 | 92 | 0.010 |
Why?
| | Phosphotransferases | 1 | 2003 | 24 | 0.010 |
Why?
| | Class Ib Phosphatidylinositol 3-Kinase | 1 | 2003 | 4 | 0.010 |
Why?
| | bcl-Associated Death Protein | 1 | 2003 | 9 | 0.010 |
Why?
| | Aconitate Hydratase | 1 | 2003 | 17 | 0.010 |
Why?
| | Toll-Like Receptors | 1 | 2004 | 185 | 0.010 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2003 | 162 | 0.010 |
Why?
| | Algorithms | 1 | 2010 | 1689 | 0.010 |
Why?
| | Lipid Peroxidation | 1 | 2003 | 153 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3264 | 0.010 |
Why?
| | Mice, Mutant Strains | 1 | 2003 | 297 | 0.010 |
Why?
| | Extracellular Space | 1 | 2003 | 119 | 0.010 |
Why?
| | Metalloporphyrins | 1 | 2003 | 103 | 0.010 |
Why?
| | Replication Protein C | 1 | 2001 | 4 | 0.010 |
Why?
| | Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2001 | 11 | 0.010 |
Why?
| | bcl-X Protein | 1 | 2001 | 43 | 0.010 |
Why?
| | Toll-Like Receptor 4 | 1 | 2004 | 273 | 0.010 |
Why?
| | Biological Transport | 1 | 2003 | 416 | 0.010 |
Why?
| | Cysteine Endopeptidases | 1 | 2001 | 72 | 0.010 |
Why?
| | Protein Kinases | 1 | 2003 | 319 | 0.010 |
Why?
| | CREB-Binding Protein | 1 | 2001 | 31 | 0.010 |
Why?
| | Transcription Factor RelA | 1 | 2001 | 87 | 0.010 |
Why?
| | Tungsten | 1 | 2001 | 30 | 0.010 |
Why?
| | Animal Feed | 1 | 2001 | 53 | 0.010 |
Why?
| | Immune Sera | 1 | 2000 | 88 | 0.010 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2001 | 185 | 0.010 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 185 | 0.010 |
Why?
| | Organ Specificity | 1 | 2000 | 304 | 0.010 |
Why?
| | Endotoxins | 1 | 2000 | 220 | 0.010 |
Why?
| | Protein Biosynthesis | 1 | 2001 | 430 | 0.010 |
Why?
| | Antioxidants | 1 | 2003 | 584 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2003 | 769 | 0.010 |
Why?
| | Intubation, Intratracheal | 1 | 2000 | 257 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2010 | 10744 | 0.010 |
Why?
| | Peptides | 1 | 2001 | 979 | 0.010 |
Why?
| | Proteins | 1 | 2001 | 1008 | 0.010 |
Why?
|
|
Arcaroli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|